Literature DB >> 20188706

Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells.

Makoto Kinoshita1, Yuji Nakatsuji, Takashi Kimura, Masayuki Moriya, Kazushiro Takata, Tatsusada Okuno, Atsushi Kumanogoh, Koji Kajiyama, Hiroo Yoshikawa, Saburo Sakoda.   

Abstract

Neuromyelitis optica (NMO) is an inflammatory demyelinating disease of the central nervous system (CNS). Anti-aquaporin-4 antibody (AQP4-Ab) is a highly specific serum autoantibody that is detected in patients with NMO. Several lines of evidence indicate that AQP4-Ab not only serves as a disease marker but also plays a pivotal role in the pathogenesis of NMO. Although the pathogenicity of AQP4-Ab in vivo has recently been demonstrated, the presence of CNS antigen-specific T cells is recognized as a prerequisite for the antibody to exert pathogenic effects. Thus, it remains unclear whether AQP4-Ab is the primary cause of the disease or a disease-modifying factor in NMO. Here we report that pre-treatment with complete Freund's adjuvant (CFA) alone is sufficient for AQP4-Ab to induce astrocytic damage in vivo. Our results show the primary pathogenic role of AQP4-Ab in the absence of CNS antigen-specific T cells, and suggest that danger signals provided by nonspecific inflammation can be a trigger for those who harbor the autoantibody to develop NMO. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20188706     DOI: 10.1016/j.bbrc.2010.02.157

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  38 in total

Review 1.  The innate immune system in demyelinating disease.

Authors:  Lior Mayo; Francisco J Quintana; Howard L Weiner
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

2.  Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms.

Authors:  Hua Zhang; Jeffrey L Bennett; A S Verkman
Journal:  Ann Neurol       Date:  2011-11-08       Impact factor: 10.422

Review 3.  Biology of AQP4 and anti-AQP4 antibody: therapeutic implications for NMO.

Authors:  A S Verkman; Puay-Wah Phuan; Nithi Asavapanumas; Lukmanee Tradtrantip
Journal:  Brain Pathol       Date:  2013-11       Impact factor: 6.508

4.  Treatment of Neuromyelitis Optica: Review and Recommendations.

Authors:  Dorlan J Kimbrough; Kazuo Fujihara; Anu Jacob; Marco A Lana-Peixoto; Maria Isabel Leite; Michael Levy; Romain Marignier; Ichiro Nakashima; Jacqueline Palace; Jérôme de Seze; Olaf Stuve; Silvia N Tenembaum; Anthony Traboulsee; Emmanuelle Waubant; Brian G Weinshenker; Dean M Wingerchuk
Journal:  Mult Scler Relat Disord       Date:  2012-10       Impact factor: 4.339

Review 5.  Autoimmune epilepsies.

Authors:  Christian G Bien; Jan Bauer
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

Review 6.  Experimental models of neuromyelitis optica: current status, challenges and future directions.

Authors:  Minshu Li; Yaping Yan
Journal:  Neurosci Bull       Date:  2015-06-24       Impact factor: 5.203

7.  Absence of cortical demyelination in neuromyelitis optica.

Authors:  B F Gh Popescu; J E Parisi; J A Cabrera-Gómez; K Newell; R N Mandler; S J Pittock; V A Lennon; B G Weinshenker; C F Lucchinetti
Journal:  Neurology       Date:  2010-12-07       Impact factor: 9.910

8.  Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1/M23 isoforms and orthogonal arrays.

Authors:  Jonathan M Crane; Chiwah Lam; Andrea Rossi; Tripta Gupta; Jeffrey L Bennett; A S Verkman
Journal:  J Biol Chem       Date:  2011-03-21       Impact factor: 5.157

9.  Review of Animal Models of Neuromyelitis Optica.

Authors:  Melina V Jones; Nicolas Collongues; Jerome de Seze; Makoto Kinoshita; Yuji Nakatsuji; Michael Levy
Journal:  Mult Scler Relat Disord       Date:  2012-10       Impact factor: 4.339

10.  Unique neuromyelitis optica pathology produced in naïve rats by intracerebral administration of NMO-IgG.

Authors:  Nithi Asavapanumas; Julien Ratelade; A S Verkman
Journal:  Acta Neuropathol       Date:  2013-11-05       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.